Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue

• Immunology deals with physiological functioning of the immune system in states of both health and disease as well as malfunctions of the immune system in immunological disorders
• With the new advancement in immune sector, global pharmaceuticals continue to grow in the field despite the disruption during the COVID-19. As in 2019, Abbvie again secured the top position with total revenue of $22.15B, followed by J&J, Roche, and Amgen
• Our team at PharmaShots has compiled a list of top 20 immunology companies based on their 2020 immunology revenue

Antares Pharma is a specialty pharmaceutical company focused primarily on the development & commercialization of pharmaceutical products and technologies addressing the unmet needs in the targeted therapeutic areas. The company has reported a total sale of $0.015B from its immunology segment in 2020 from the sales of Otrexup in RA, pJIA, Psoriasis.

3S Bio is a Chinese Biotechnology company that focuses on oncology, nephrology, dermatology, and auto-immune diseases. The company unveiled the total sales of $0.09B in its immunology segment during the year 2020 from the sales of Yisaipu, which is a TNF α inhibitor indicated to treat RA, AS and psoriasis.

GSK is a global healthcare multinational company involves in the development, manufacture, and marketing of pharmaceutical products, vaccines, OTC medicines, and health-related consumer products. With only approved products, Benlysta, GSK has generated a revenue of $0.99B in 2020. In Dec 2020, the US FDA has approved Benlysta as the first medicine for adult patients with active LN.

Horizon is a biopharmaceutical company that focuses on rare and rheumatic diseases. Horizon has generated the sale of $1.05B from its four approved immunology products including Tepezza, Rayos, Duexis, and Vimovo. During the fiscal year 2020, Tepezza alone has generated $820M revenue, followed by Duexis ($125.3M), Rayos ($71.8M), and Vimovo ($37.6M).

Mitsubishi Tanabe Pharma Corporation (MTPC) is a Japanese pharmaceutical company that focuses on diabetes, kidney diseases, autoimmune diseases, and vaccines. The company has reported a total sale of $1.08B from its immunology segment in 2020. In Dec’ 2020 MTPC initiates a long-term OLE trial to the phase III MT-1186-A03 trial of edaravone for Amyotrophic lateral sclerosis

Merck & Co. is an American multinational pharmaceutical company. The company develops medicines (oncology, OTC, and generic drugs), vaccines, biologic therapies, and animal health products. In 2020, Merck-approved drugs including Simponi and Remicade generated revenue of $1.16B.

Astellas is a Japanese multinational pharmaceutical company. It focuses on serving patients’ medical needs across multiple therapeutic areas, including cardiology, hematology, immunology, infectious diseases, oncology, and urology. Astellas immune drug, Prograf generated revenue of $1.65B in 2020. In Jan’2020, Astellas announced the construction of a new manufacturing facility for Prograf’s API in the Toyama technology center.

Incyte is a global biopharmaceutical company that focuses on oncology, inflammation, and autoimmune diseases. In 2020, Incyte has generated revenue of $1.93B in its immunology segment. In Jul’2020, Incyte and MorphoSys announced that the FDA approved Monjuvi (tafasitamab-cxix), which is indicated in combination with lenalidomide for R/R DLBCL

Biogen is a US-based biotechnology company that focuses on developing and delivering innovative therapies globally for neurological, neurodegenerative, and autoimmune diseases. Major areas of it include MS, neuroimmunology, neuromuscular disorders including Spinal Muscular Atrophy (SMA), movement disorders including Parkinson’ disease, Ophthalmology, and neuropsychiatry. Biogen generated a revenue of $1.94 with Tysabri in the immunology segment. In Jun’2020, the company submitted the regulatory filing of Tysabri in the US and the EU.

UCB is a multinational biopharmaceutical company that specializes in two therapeutic areas, the central nervous system (CNS) and immunology. Cimzia has generated total revenue of $2.1B in 2020. In Jan’2020, UCB’s biologic Cimzia (certolizumab pegol) was approved by MHRA for the treatment of PsO, PsA, pustular psoriasis, and psoriatic erythroderma for which existing treatment methods are not sufficiently effective. The approval makes Cimzia the first Fc-free, PEGylated anti-TNF treatment option in Japan.

Eli Lilly is an American pharmaceutical company focused on immunology, neurodegenerative diseases, and endocrinology. Eli Lilly has two approved immunology products including Olumiant and Taltz. Its immune product, Taltz has generated revenue of $1.78B while the remaining is from Olumiant’s sales in 2020. Taltz and Olumiant drove the 37% increase in revenue in Immunology.

BMS is a global biopharmaceutical company that focuses on multiple therapeutic areas including oncology, hematology, cardiovascular, and immunology. Its immune drug, Orencia generated revenue of $3.16 in 2020. The revenue of Orencia increased by 6% and 7% in the US and international market due to higher demand respectively. In Jun’2020, the company reported results of an open-label P-IV Early AMPLE biomarker study assessing the differences by which Orencia and adalimumab interfere with disease progression in the mod. to sev. RA patients.

Takeda is a Japanese multinational biopharmaceutical company. It is one of the top 20 largest pharmaceutical companies in the world by revenue. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary. With Takeda’s immunology-approved drugs including Immunoglobulin and Albumin, Takeda has generated a $3.56B sale in 2020.

Pfizer is an American multinational pharmaceutical company. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. Pfizer’s immune drug, Xeljanz generated revenue of $2.43B, followed by Enbrel ($1.35B) and inflectra ($0.65B) in 2020. In Sept’2020, the US FDA approved Xeljanz (tofacitinib) for the treatment of children and adolescents aged≥2yrs. with active pcJIA.

Sanofi is a French multinational pharmaceutical company. The company covers seven major therapeutic areas; cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Dupixent and Kevzara together contributed to the $4.60B revenue of the company in the immunology segment.  In November 2020, Dupixent (dupilumab) was approved by European Commission as the first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis.

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. The company is focused on immunology, Hepatology, Dermatology, oncology, Neurology, and Ophthalmology. Novartis’ immune drug, Cosentyx generated revenue of $3.9B and Ilaris generated 0.87B in 2020. Cosentyx received approval and launched in the EU and US for nr-axSpA, its fourth major indication, and in August became the first treatment approved in Japan for this indication. In April, Cosentyx also became the first IL17A inhibitor approved in China for the treatment of AS. In June, Ilaris was granted a new indication in the US for active Still’s disease including Adult-Onset Still’s Disease (AOSD).

Amgen is an American multinational biopharmaceutical company that focuses on CV disease, oncology, bone health, neuroscience, immunology, nephrology, and inflammation. In 2020, Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis generated total sales of $4.9B whereas Otezla which is a PDE4 inhibitor generated a revenue of $2.1B.

Roche is a Swiss multinational healthcare company. The immunology department of the company focuses on rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. Roche’s immunotherapies include Actemra, Xolair, Esbriet, MabThera, Pulmozyme, CellCept, and others.  Actemra produces the highest revenue among all with $3.23B.

Johnson and Johnson is an American multinational company that focuses on multiple therapeutic areas including Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. In its immunology segment, J&J focuses on core diseases like rheumatoid arthritis, inflammatory bowel diseases, and psoriasis. In 2020, its leading immunology product, Stelara generated sales of $7.70B, followed by Remicade, Simponi, and Tremfya with the revenue of $3.74B, $2.24B, and $1.34B respectively.

Abbvie is an American Biopharmaceutical company focused on the development of products in immunology, oncology, virology and neuroscience, dermatology. In Dec’2020, Abbvie announced that CHMP recommended the approval of Rinvoq for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patients with active ankylosing spondylitis. In 2020, Abbvie immune drugs, Humira generated total sales of $19.83B, Skyrizi generated $1.59B whereas Rinvoq achieved $0.73B sales.

Source: Company annual reports, SEC filings, press releases, and company websites

Market Cap source: Google finance (as of 12th Aug 2021)

All revenues are reported in USD.

Related Post: Top 20 Immunology Companies Based 2019 Immunology Segment Revenue